Parkinson J F, Vlahos C J, Yan S C, Bang N U
Lilly Laboratories for Clinical Research, Indianapolis 46202.
Biochem J. 1992 Apr 1;283 ( Pt 1)(Pt 1):151-7. doi: 10.1042/bj2830151.
Two glycoforms of a secretable human thrombomodulin mutant [TMD1-105 and TMD1-75; Parkinson, Grinnell, Moore, Hoskins, Vlahos & Bang (1990) J. Biol. Chem. 265, 12602-12610] were expressed in human 293 cells and used to study the role of glycosylation in the functions of this endothelial-cell thrombin receptor. Carbohydrate content analysis and intrinsic labelling with [3H]glucosamine and [35S]sulphate showed that TMD1-105 contained a chondroitin sulphate whereas TMD1-75 did not. Other than chondroitin sulphate, the carbohydrate contents of the two glycoforms were identical, indicating similar glycosylation patterns at other O-linked and N-linked sites in the two glycoforms. The properties of TMD1-105 were converted into those of TMD1-75 by chondroitin ABC lyase digestion. Trypsin digestion of labelled TMD1-105 permitted isolation of two overlapping peptides that contained chondroitin sulphate, spanned the entire O-glycosylation domain and had O-glycosylation sites at Ser-492, Ser-498, Thr-500, Thr-504 and Thr-506. The chondroitin sulphate-attachment site was assigned to Ser-492 as this residue is conserved in mouse and bovine thrombomodulin and lies within a sequence Ser-Gly-Ser-492-Gly-Glu-Pro, which has strong similarity to chondroitin sulphate attachment sites in other proteoglycans. Five peptides with N-linked carbohydrate were also isolated and contained glycosylation sites in the lectin-like domain (Asn-47, Asn-115, Asn-116) and in the fourth (Asn-382) and fifth (Asn-409) epidermal growth factor domains. The role of N-linked and simple O-linked carbohydrates in the functions of human thrombomodulin remain unclear. The present studies demonstrate, however, that the presence of chondroitin sulphate in human thrombomodulin has profound effects on all of the anticoagulant properties of this important anticoagulant thrombin receptor.
一种可分泌的人血栓调节蛋白突变体的两种糖型[TMD1 - 105和TMD1 - 75;帕金森、格林内尔、摩尔、霍斯金斯、弗拉霍斯和邦(1990年)《生物化学杂志》265卷,12602 - 12610页]在人293细胞中表达,并用于研究糖基化在这种内皮细胞凝血酶受体功能中的作用。碳水化合物含量分析以及用[³H]葡糖胺和[³⁵S]硫酸盐进行的内在标记表明,TMD1 - 105含有硫酸软骨素,而TMD1 - 75则没有。除硫酸软骨素外,这两种糖型的碳水化合物含量相同,表明这两种糖型在其他O - 连接和N - 连接位点具有相似的糖基化模式。通过硫酸软骨素ABC裂解酶消化,TMD1 - 105的特性转变为TMD1 - 75的特性。对标记的TMD1 - 105进行胰蛋白酶消化,可分离出两个重叠的肽段,它们含有硫酸软骨素,跨越整个O - 糖基化结构域,并且在Ser - 492、Ser - 498、Thr - 500、Thr - 504和Thr - 506处具有O - 糖基化位点。硫酸软骨素连接位点被确定为Ser - 492,因为该残基在小鼠和牛的血栓调节蛋白中保守,并且位于序列Ser - Gly - Ser - 492 - Gly - Glu - Pro内,该序列与其他蛋白聚糖中的硫酸软骨素连接位点具有很强的相似性。还分离出了五个带有N - 连接碳水化合物的肽段,它们在凝集素样结构域(Asn - 47、Asn - 115、Asn - 116)以及第四(Asn - 382)和第五(Asn - 409)个表皮生长因子结构域中含有糖基化位点。N - 连接和简单O - 连接碳水化合物在人血栓调节蛋白功能中的作用仍不清楚。然而,目前的研究表明,人血栓调节蛋白中硫酸软骨素的存在对这种重要的抗凝血凝血酶受体的所有抗凝血特性都有深远影响。